Estados financieros detallados de Eupraxia Pharmaceuticals Inc. (EPRX): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $8.09, EPRX presenta beneficios negativos (P/E no significativo) y un ROE del -45.29%. La capitalización bursátil es de $271M.
Cuenta de Resultados (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $86623 | $125426 | $207440 | $117072 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | -$86623 | -$125426 | -$207440 | -$117072 | 0 | 0 | 0 | 0 | 0 |
| I+D | $3.4M | $6.8M | $3.5M | $1.1M | $10.2M | $13.6M | $15.3M | $16.1M | $21.3M |
| Generales y Administrativos | $1.5M | $5.1M | $3.1M | $1.3M | $8.2M | $4.0M | $5.6M | $10.9M | $17.1M |
| Gastos Operativos | $4.8M | $11.9M | $6.6M | $2.4M | $18.4M | $17.6M | $21.0M | $27.0M | $38.4M |
| Beneficio Operativo | -$4.9M | -$12.0M | -$6.8M | -$2.5M | -$18.4M | -$17.6M | -$21.0M | -$27.0M | -$38.4M |
| EBITDA | -$4.9M | -$14.5M | -$5.7M | -$2.0M | -$17.9M | -$17.9M | -$20.8M | -$25.0M | -$38.3M |
| Gastos por Intereses | $52806 | $142173 | $1.5M | $1.9M | $1.2M | $982856 | $881053 | $603573 | 0 |
| Beneficio Antes de Impuestos | -$5.1M | -$14.8M | -$7.4M | -$4.0M | -$24.3M | -$19.0M | -$21.8M | -$25.7M | -$38.6M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | $27423 | $1804 | $19091 |
| Beneficio Neto | -$4.4M | -$13.2M | -$7.4M | -$4.0M | -$24.0M | -$18.5M | -$21.2M | -$25.5M | -$38.6M |
| BPA | $-0.34 | $-1.03 | $-0.56 | $-0.31 | $-1.93 | $-0.96 | $-0.88 | $-0.76 | $-1.03 |
| BPA Diluido | $-0.34 | $-1.03 | $-0.56 | $-0.31 | $-1.93 | $-0.96 | $-0.88 | $-0.76 | $-1.03 |
| Acciones en Circulación (Diluidas) | $12.9M | $12.9M | $12.9M | $12.9M | $12.4M | $19.3M | $24.1M | $33.9M | $40.0M |
Balance (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $4.0M | $823481 | $1.2M | $150126 | $20.9M | $24.7M | $14.6M | $33.1M | $80.6M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | $9.0M | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | $1.3M | $1.5M | 0 | 0 | 0 | 0 | $143516 | $228872 | $674226 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $5.5M | $2.5M | $2.6M | $1.1M | $30.6M | $25.2M | $14.9M | $34.4M | $85.1M |
| Inmovilizado Material | $419438 | $435468 | $646210 | $315337 | $589068 | $718608 | $343520 | $424916 | $987126 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $5.9M | $2.9M | $3.3M | $1.5M | $31.2M | $25.9M | $15.3M | $34.9M | $86.2M |
| Cuentas por Pagar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deuda a Corto | 0 | $3.8M | $11.6M | $12.5M | $94916 | $107528 | $7.8M | 0 | 0 |
| Pasivos Corrientes | $730683 | $14.3M | $20.7M | $22.5M | $2.3M | $4.1M | $14.6M | $3.1M | $5.6M |
| Deuda a Largo | 0 | 0 | 0 | 0 | $9.7M | $11.9M | 0 | 0 | 0 |
| Pasivos Totales | $735815 | $14.3M | $21.4M | $23.1M | $12.1M | $16.1M | $14.6M | $3.1M | $5.7M |
| Reservas | -$20.1M | -$40.0M | -$47.2M | -$51.2M | -$74.3M | -$104.6M | -$79.4M | -$131.0M | -$169.6M |
| Patrimonio Neto | $6.0M | -$11.1M | -$17.7M | -$21.2M | $20.0M | $10.5M | $1.7M | $33.4M | $82.0M |
| Deuda Total | $12474 | $3.8M | $11.9M | $12.8M | $10.0M | $12.2M | $7.9M | $71859 | $154362 |
| Deuda Neta | -$4.0M | $3.0M | $10.8M | $12.6M | -$19.9M | -$12.6M | -$6.7M | -$33.0M | -$80.4M |
| Capital Circulante | $4.8M | -$11.9M | -$18.0M | -$21.4M | $28.3M | $21.0M | $323137 | $31.3M | $79.5M |
Flujo de Caja (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$5.0M | -$14.8M | -$7.2M | -$4.0M | -$18.2M | -$19.0M | -$21.8M | -$25.7M | -$39.2M |
| Amortizaciones | $85376 | $125826 | $201936 | $116809 | $88174 | $147894 | $117100 | $171719 | $241680 |
| Compensación en Acciones | $162823 | $2.9M | $544950 | $228680 | 0 | $1.4M | $1.1M | $3.2M | 0 |
| Cambio en Capital Circulante | -$599386 | $1.1M | $167540 | $730594 | -$167157 | $1.5M | $4.0M | -$6.8M | -$725601 |
| Flujo de Caja Operativo | -$5.3M | -$8.3M | -$5.2M | -$403784 | -$11.6M | -$14.4M | -$15.6M | -$30.0M | -$29.0M |
| Inversiones (CapEx) | -$314689 | -$141856 | -$9479 | 0 | -$341278 | -$235550 | -$55247 | -$104227 | -$598771 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$5.6M | -$8.5M | -$5.2M | -$403784 | -$11.9M | -$14.6M | -$15.7M | -$30.1M | -$29.6M |
Crecimiento y Márgenes (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Crecimiento Beneficio Neto (anual) | -201.1% | +44.1% | +45.7% | -498.0% | +22.8% | -14.9% | -20.0% | -51.3% | |
| Crecimiento BPA (anual) | -202.9% | +45.6% | +44.6% | -522.6% | +50.3% | +8.3% | +13.6% | -35.5% | |
| Cambio en Acciones (anual) | +0.0% | +0.0% | +0.0% | -3.6% | +55.5% | +25.2% | +40.5% | +17.8% | |
| Crecimiento FCF (anual) | -50.8% | +38.8% | +92.2% | -2851.3% | -22.8% | -7.2% | -92.0% | +1.6% | |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.1% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $-0.44 | $-0.66 | $-0.40 | $-0.03 | $-0.96 | $-0.76 | $-0.65 | $-0.89 | $-0.74 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $12.9M | $12.9M | $12.9M | $12.9M | $12.4M | $19.3M | $24.1M | $33.9M | $40.0M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -45.29% |
| Rentabilidad sobre capital invertido | -43.07% |
| Rentabilidad sobre activos | -35.72% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.01 |
| Ratio corriente | 16.00 |
Ratios Clave (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| P/E | -10.92 | -3.91 | -6.84 | -12.14 | -1.93 | -4.16 | -3.35 | -4.17 | -7.33 |
| P/VC | 7.99 | -4.68 | -2.78 | -2.28 | 2.32 | 7.31 | 42.69 | 3.22 | 3.68 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Empresas relacionadas: AARD · GNFT · IVA · MDWD · NAUT · NTHI · OBIO
Explorar sector: Healthcare · Biotechnology
Más secciones de EPRX: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones